1 |
Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, et al. : Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw 10 : 939-942, 2012
DOI
|
2 |
Hersh JH; American Academy of Pediatrics Committee on Genetics : Health supervision for children with neurofibromatosis. Pediatrics 121 : 633-642, 2008
DOI
|
3 |
Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. : Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5 : 104, 2010
DOI
|
4 |
Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al. : Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19 : 1047-1057, 2017
DOI
|
5 |
Huttner AJ, Kieran MW, Yao X, Cruz L, Ladner J, Quayle K, et al. : Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer 54 : 890-896, 2010
|
6 |
Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, et al. : Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet 52 : 770-778, 2015
DOI
|
7 |
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. : PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 : 2509-2520, 2015
DOI
|
8 |
Lemery S, Keegan P, Pazdur R : First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med 377 : 1409-1412, 2017
DOI
|
9 |
Hanahan D, Weinberg RA : Hallmarks of cancer: the next generation. Cell 144 : 646-674, 2011
DOI
|
10 |
Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. : A cancer family syndrome in twenty-four kindreds. Cancer Res 48 : 5358-5362, 1988
|
11 |
Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein JL, Claus E, et al. : GLIOGENE an international consortium to understand familial glioma. Cancer Epidemiol Biomarkers Prev 16 : 1730-1734, 2007
DOI
|
12 |
Mai P, Malkin D, Garber JE, Schiffman JD Weitzel JN, Strong LC, et al. : Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet 205 : 479-487, 2012
DOI
|
13 |
Malkin D : Li-Fraumeni syndrome. Genes Cancer 2 : 475-484, 2011
DOI
|
14 |
Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. : Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 : 1233-1238, 1990
DOI
|
15 |
Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, et al. : A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10 : 55-62, 2001
DOI
|
16 |
Ranger A, Szymczak A, Hammond RR, Zelcer S : Pediatric thalamic glioblastoma associated with Ollier disease (multiple enchondromatosis): a rare case of concurrence. J Neurosurg Pediatr 4 : 363-367, 2009
DOI
|
17 |
Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. : Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging. JAMA Oncol 3 : 1634-1639, 2017
DOI
|
18 |
Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, et al. : Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23 : e68-e75, 2017
DOI
|
19 |
Reyes D, Prayson R : Glioblastoma in the setting of tuberous sclerosis. J Clin Neurosci 22 : 907-908, 2015
DOI
|
20 |
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. : Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 : 124-128, 2015
DOI
|
21 |
Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, et al. : A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19 : 1135-1144, 2017
DOI
|
22 |
Bleeker FE, Hopman SMJ, Merks JHM, Aalfs CM, Hennekam RC : Brain tumors and syndromes in children. Neuropediatrics 45 : 137-161, 2014
DOI
|
23 |
Wimmer K, Rosenbaum T, Messiaen L : Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet 91 : 507-519, 2017
DOI
|
24 |
Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. : Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373 : 2336-2346, 2015
DOI
|
25 |
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. : Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31 : 2927-35, 2013
DOI
|
26 |
Gozali AE, Britt B, Shane L, Gonzalez I, Gilles F, McComb JG, et al. : Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer 58 : 905-909, 2012
DOI
|
27 |
Elmariah SB, Huse J, Mason B, Leroux P, Lustig RA : Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer. Breast J 12 : 470-474, 2006
DOI
|
28 |
Esteban-Jurado C, Gimenez-Zaragoza D, Munoz J, Franch-Exposito S, alvarez-Barona M, Ocana T, et al. : POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget 8 : 26732-26743, 2017
|
29 |
Ligtenberg MJL, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. : Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41 : 112-117, 2009
DOI
|
30 |
Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, et al. : Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet 99 : 337-351, 2016
DOI
|
31 |
Albers AC, Gutmann DH : Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother 9 : 535-539, 2009
DOI
|
32 |
Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, et al. : High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138 : 380-385, 2016
DOI
|
33 |
Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP : Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96 : 238-242, 2001
DOI
|
34 |
Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. : Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28 : 3061-3068, 2010
DOI
|
35 |
Listernick R, Ferner RE, Liu GT, Gutmann DH : Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61 : 189-198, 2007
DOI
|
36 |
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK : WHO classification of tumours of the central nervous system, ed 4. Lyon : International Agency for Research on Cancer Publications, 2016
|
37 |
Grill J, Laithier V, Rodriguez D, Raquin MA, Pierre-Kahn A, Kalifa C : When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 159 : 692-696, 2000
DOI
|
38 |
Khatua S, Gutmann DH, Packer RJ : Neurofibromatosis type 1 and optic pathway glioma: molecular interplay and therapeutic insights. Pediatr Blood Cancer 65 : e26838, 2017
|
39 |
King A, Listernick R, Charrow J, Piersall L, Gutmann DH : Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet 122A : 95-99, 2003
DOI
|
40 |
Kinsella TJ : Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 15 : 1853-1859, 2009
DOI
|
41 |
Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, et al. : Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Fam Cancer 16 : 433-440, 2017
DOI
|
42 |
Rosenfeld A, Listernick R, Charrow J, Goldman S : Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 26 : 663-667, 2010
DOI
|
43 |
Rosser T, Packer RJ : Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 17 : 630-637; discussion 646-651, 2002
DOI
|
44 |
Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, et al. : Regression of chemotherapy-resistant polymerase (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res 22 : 5682-5687, 2016
DOI
|
45 |
Varan A, Sen H, Aydin B, Yalcin B, Kutluk T, Akyuz C : Neurofibromatosis type 1 and malignancy in childhood. Clin Genet 89 : 341-345, 2016
DOI
|
46 |
Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, et al. : 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27 : e108-e109; author reply e110, 2009
DOI
|
47 |
Unger PD, Taff ML, Song S, Schwartz IS : Sudden death in a patient with Von Recklinghausen's neurofibromatosis. Am J Forensic Med Pathol 5 : 175-179, 1984
DOI
|
48 |
Uyttebroeck A, Legius E, Brock P, Van de Cassey W, Casaer P, Casteels-Van Daele M : Consecutive glioblastoma and B cell non-Hodgkin's lymphoma in a young child with von Recklinghausen's neurofibromatosis. Med Pediatr Oncol 24 : 46-49, 1995
DOI
|
49 |
Villani A, Malkin D, Tabori U : Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises. Curr Neurol Neurosci Rep 12 : 153-164, 2012
DOI
|
50 |
de Andrade KC, Mirabello L, Stewart DR, Karlins E, Koster R, Wang M, et al. : Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. Hum Mutat 38 : 1723-1730, 2017
DOI
|
51 |
Bouffet E, Larouche V, Campbell BB, Merico D, De Borja R, Aronson M, et al. : Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34 : 2206-2211, 2016
DOI
|
52 |
Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. : Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33 : 2345-2352, 2015
DOI
|
53 |
Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D : Pediatric cancer predisposition and surveillance: an overview, and a tribute to Alfred G. Knudson Jr. Clin Cancer Res 23 : e1-e5, 2017
DOI
|
54 |
Broekman ML, Risselada R, Engelen-Lee J, Spliet WG, Verweij BH : Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I. Case Rep Med 2009 : 757898, 2009
|
55 |
Distelmaier F, Fahsold R, Reifenberger G, Messing-Juenger M, Schaper J, Schneider DT, et al. : Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Child's Nerv Syst 23 : 343-347, 2007
DOI
|
56 |
Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, et al. : Comprehensive analysis of hypermutation in human cancer. Cell 171 : 1042-1056.e10, 2017
DOI
|
57 |
Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008
DOI
|
58 |
Cruz GR, Dias Oliveira I, Moraes L, Del Giudice Paniago M, De Seixas Alves MT, Capellano AM, et al. : Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J Neurooncol 117 : 235-242, 2014
DOI
|
59 |
Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. : Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44 : 81-88, 2006
DOI
|
60 |
Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Schneider KW, et al. : Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res 23 : e46-e53, 2017
DOI
|
61 |
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, et al. : Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14 : 790-797, 2012
DOI
|
62 |
Girardstein-Boccara L, Mari V, Met-Domestici M, Burel-Vandenbos F, Berthet P, Paquis P, et al. : Gliomas and BRCA genes mutations: fortuitous association or imputability? Bull Cancer 101 : 795-802, 2014
|
63 |
Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. : Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27 : 1250-1256, 2009
DOI
|
64 |
Goudie C, Coltin H, Witkowski L, Mourad S, Malkin D, Foulkes WD : The McGill Interactive Pediatric OncoGenetic Guidelines: an approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. Pediatr Blood Cancer 64 : e26441, 2017
DOI
|
65 |
Jalali A, Amirian ES, Bainbridge MN, Armstrong GN, Liu Y, Tsavachidis S, et al. : Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene consortium. Sci Rep 5 : 8278, 2015
DOI
|
66 |
Jett K, Friedman JM : Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12 : 1-11, 2010
|
67 |
Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, et al. : Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 23 : e38-e45, 2017
DOI
|
68 |
Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H : Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150 : 1-13, 1997
|
69 |
Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. : Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov 6 : 1230-1236, 2016
DOI
|
70 |
Knapke S, Nagarajan R, Correll J, Kent D, Burns K : Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr Blood Cancer 58 : 85-89, 2012
DOI
|
71 |
Kyritsis AP, Bondy ML, Rao JS, Sioka C : Inherited predisposition to glioma. Neuro Oncol 12 : 104-113, 2010
DOI
|
72 |
Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, et al. : Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361 : 1101-1102, 2003
DOI
|
73 |
McKeever K, Shepherd CW, Crawford H, Morrison PJ : An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age. Ulster Med J 77 : 160-163, 2008
|
74 |
Menor F, Marti-Bonmati L, Mulas F, Cortina H, Olague R : Imaging considerations of central nervous system manifestations in pediatric patients with neurofibromatosis type 1. Pediatr Radiol 21 : 389-394, 1991
DOI
|
75 |
Miaux Y, Guermazi A, Cornu P, Mokhtari K, Singer B, Chiras J, et al. : Highintensity lesion on T1-weighted MR images in neurofibromatosis type 1: a case of premalignant lesion. Acta Neurochir (Wien) 139 : 1085-1087, 1997
DOI
|
76 |
Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. : Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 314 : 913-925, 2015
DOI
|
77 |
Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, et al. : Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. Eur J Cancer 84 : 290-303, 2017
DOI
|
78 |
Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al. : Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346 : 420-427, 2002
DOI
|
79 |
Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. : Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17 : 1295-1305, 2016
DOI
|
80 |
Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, et al. : Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol 33 : 602-609, 2015
DOI
|
81 |
Bogler O, Su Huang HJ, Kleihues P, Cavenee WK : The p53 gene and its role in human brain tumors. Glia 15 : 308-327, 1995
DOI
|
82 |
Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, et al. : Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer, 2017 [Epub ahead of print]
|
83 |
Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, et al. : Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the gliogene consortium. Cancer Res 71 : 7568-7575, 2011
DOI
|
84 |
Shibahara I, Sonoda Y, Suzuki H, Mayama A, Kanamori M, Saito R, et al. : Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Brain Tumor Pathol 1 : 10-18, 2018
|
85 |
Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. : Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet 47 : 257-262, 2015
DOI
|
86 |
Dodgshun AJ, Sexton-Oates A, Saffery R, Sullivan MJ : Biallelic FANCD1/BRCA2 mutations predisposing to glioblastoma multiforme with multiple oncogenic amplifications. Cancer Genet 209 : 53-56, 2016
DOI
|
87 |
Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H : Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117 : 653-656, 2009
DOI
|
88 |
Kaufman DK, Kimmel DW, Parisi JE, Michels VV : A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 43 : 1728-1731, 1993
DOI
|
89 |
Wimmer K, Etzler J : Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 124 : 105-122, 2008
DOI
|
90 |
Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. : Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium "Care for CMMRD" (C4CMMRD). J Med Genet 51 : 355-365, 2014
DOI
|
91 |
Dudley JC, Lin MT, Le DT, Eshleman JR : Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22 : 813-820, 2016
DOI
|
92 |
Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, et al. : Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology 152 : 1605-1614, 2017
DOI
|
93 |
Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA : Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 56 : 7-15, 2011
DOI
|
94 |
Eisenstat DD, Pollack IF, Demers A, Sapp MV, Lambert P, Weisfeld-Adams JD, et al. : Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. J Neurooncol 121 : 573-581, 2015
DOI
|
95 |
Guillamo JS, Creange A, Kalifa C, Grill J, Rodriguez D, Doz F, et al. : Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126(Pt 1) : 152-160, 2003
DOI
|
96 |
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008
DOI
|
97 |
Gutmann DH, James CD, Poyhonen M, Louis DN, Ferner R, Guha A, et al. : Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 61 : 1397-1400, 2003
DOI
|
98 |
Hakan T, Aker FV : Case report on a patient with neurofibromatosis type 1 and a frontal cystic glioblastoma. Neurol Neurochir Pol 42 : 362-365, 2008
|
99 |
Kandoth C, Mclellan MD, Vandin F, Ye K, Niu B, Lu C, et al. : Mutational landscape and significance across 12 major cancer types. Nature 502 : 333-339, 2013
DOI
|
100 |
Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. : Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63 : 6643-6650, 2003
|
101 |
Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, et al. : Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol 2 : 616-624, 2016
DOI
|
102 |
Patil S, Chamberlain RS : Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist 17 : 101-116, 2012
DOI
|
103 |
Scheffzek K, Ahmadian MR, Wiesmuller L, Kabsch W, Stege P, Schmitz F, et al. : Structural analysis of the GAP-related domain from neurofibromin and its implications. EMBO J 17 : 4313-4327, 1998
DOI
|
104 |
Schneider K, Zelley K, Nichols KE, Garber J : Li-Fraumeni syndrome in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) : . Seattle : University of Washington, 1993
|
105 |
Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, et al. : Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24 : 2570-2575, 2006
DOI
|
106 |
Sherborne AL, Lavergne V, Yu K, Lee L, Davidson PR, Mazor T, et al. : Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors. Clin Cancer Res 23 : 1852-1861, 2017
DOI
|
107 |
Tabori U, Laberge AM, Ellezam B, Carret AS : Cancer Predisposition in Children with Brain Tumors : Pediatric Neuro-oncology. New York : Springer New York, 2015, pp69-89
|
108 |
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. : The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131 : 803-820, 2016
DOI
|
109 |
Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, et al. : Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28 : 1345-1350, 2010
DOI
|
110 |
Tabori U, Hansford JR, Achatz MI, Kratz CP, Plon SE, Frebourg T, et al. : Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin Cancer Res 23 : e32-e37, 2017
DOI
|
111 |
Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, et al. : TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28 : 1995-2001, 2010
DOI
|
112 |
Andrianova MA, Chetan GK, Sibin MK, Mckee T, Merkler D, Narasinga RK, et al. : Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours. J Pathol 243 : 331-341, 2017
DOI
|
113 |
Aubrey BJ, Strasser A, Kelly GL : Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med 6 : a026062, 2016
DOI
|
114 |
Baas AF, Gabbett M, Rimac M, Kansikas M, Raphael M, Nievelstein RAJ, et al. : Agenesis of the corpus callosum and gray matter heterotopia in three patients with constitutional mismatch repair deficiency syndrome. Eur J Hum Genet 21 : 55-61, 2013
DOI
|
115 |
Bainbridge MN, Armstrong GN, Gramatges MM, Bertuch AA, Jhangiani SN, Doddapaneni H, et al. : Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst 107 : 384, 2015
|
116 |
Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. : Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 50 : 987-996, 2014
DOI
|